Browsing Tag
Acrivon Therapeutics
2 posts
Acrivon Therapeutics strengthens precision oncology pipeline with ACR-368 Phase 2b success and new AP3-enabled candidates
Find out how Acrivon Therapeutics is advancing precision oncology with positive ACR-368 Phase 2b data, EU trial expansion, and new AP3-enabled pipeline candidates.
January 8, 2026
FDA grants breakthrough device designation to Acrivon’s OncoSignature assay for endometrial cancer
Acrivon Therapeutics has secured a Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its…
February 5, 2025